Business
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Feb. 12, 2026 /PRNewswire-PRWeb/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."","length":386,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Notice of Allowance confirms that the USPTO has allowed all pending claims in the application, moving the patent toward formal issuance.","length":140,"tagName":"p"},{"type":"text","content":"This patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses, positioning Hoth at the forefront of next-generation immunomodulatory therapies.","length":198,"tagName":"p"},{"type":"text","content":"Strategic Importance","length":20,"tagName":"p"},{"type":"text","content":"The allowed claims cover methods directed at:","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Exon skipping a critical component of the high-affinity IgE receptor pathway central to allergic disease activation","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Modulation of MS4A6A, a gene associated with immune signaling and inflammatory regulation","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Combination therapeutic strategies designed to reduce hypersensitivity respons...